Immunovant, Inc. (IMVT)
26.40
+0.04
(+0.15%)
USD |
NASDAQ |
Feb 20, 14:52
Immunovant Research and Development Expense (Quarterly) : 98.92M for Dec. 31, 2025
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Boston Scientific Corp. | 569.00M |
| Viridian Therapeutics, Inc. | 86.15M |
| Plus Therapeutics, Inc. | 2.436M |
| Nutriband, Inc. | 0.4571M |
| Definium Therapeutics, Inc. | 30.98M |